Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243592 · ClinicalTrials.gov registry record
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
A clinical trial of Malignant Neoplasm, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- 170
- Enrollment target
- 20
- Study locations
NCT02243592 is a study of Malignant Neoplasm that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 170 participants, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT02243592, a study of Malignant Neoplasm, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This pilot research trial studies molecular profiling in tissue samples from patients with cancer who got better with treatment that didn't work for most other patients with the same disease. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to how well patients respond to treatment.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente-Fresno - Fresno
- Kaiser Permanente-Oakland - Oakland
- Kaiser Permanente-Richmond - Richmond
- UCSF Medical Center-Mission Bay - San Francisco
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
- Kaiser Permanente-Santa Rosa - Santa Rosa
- Kaiser Permanente-Stockton - Stockton
- Kaiser Permanente-Walnut Creek - Walnut Creek
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
- John B Amos Cancer Center - Columbus
- South Georgia Medical Center/Pearlman Cancer Center - Valdosta
Colorado
- UCHealth University of Colorado Hospital - Aurora
- Poudre Valley Hospital - Fort Collins
Delaware
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
Connecticut
- Greenwich Hospital - Greenwich
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Idaho
- Saint Alphonsus Cancer Care Center-Boise - Boise
Illinois
- Rush MD Anderson Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2014-09-24 |
| Est. Completion | 2026-04-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02243592
The ClinicalTrials.gov registry entry for NCT02243592 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (67% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT02243592 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Georgia, Colorado.
Frequently Asked Questions
What is clinical trial NCT02243592 about?
NCT02243592 is a clinical study titled "Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment". This pilot research trial studies molecular profiling in tissue samples from patients with cancer who got better with treatment that didn't work for most other patients with the same disease. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cha...
What is the current status of trial NCT02243592?
This trial is currently active not recruiting. The enrollment target is 170 participants. The study started on 2014-09-24. Estimated completion is 2026-04-02.
What conditions does trial NCT02243592 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT02243592?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02243592?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02243592 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
RECRUITING · NA
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.